Description
Carfilzomib, marketed under the brand name Kyprolis, It is an prescription medication that has been approved carfilzomib in 2012, under its accelerated approval program, for use alone in patients with multiple myeloma whose cancer has progressed after receiving at least two previous therapies, including bortezomib and an immunomodulatory agent (such as lenalidomide or thalidomide).
What is Kyprolis (Carfilzomib) ?
INDICATIONS. KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone or with lenalidomide plus dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma who have received one to three lines of therapy.
Carfilzomib (marketed under the trade name Kyprolis, developed by Onyx Pharmaceuticals) is an anti-cancer drug acting as a selective proteasome inhibitor. Chemically, it is a tetrapeptide epoxyketone and an analog of epoxomicin.
How to order approved “Kyprolis (Carfilzomib) for Injection” Medicine?
Kyprolis (Carfilzomib) Injection is a prescription medicine, it can be accessed through the Named Patient Program (NPP) for treatment in the following city of India – Bengaluru, Delhi, Chennai, Hyderabad, Mumbai, Pune, Kolkata, Ahmedabad, Gurgaon. To inquire about the cost price of purchasing Kyprolis and arranging delivery to your location, please get in touch with Mr. Rakesh at +91 9910645395 or send an enquiry to info@cancermedicinesnetwork. We assure you of the quality of the product and guarantee delivery in accordance with your specific requirements.
